DE68914698D1 - Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung. - Google Patents

Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung.

Info

Publication number
DE68914698D1
DE68914698D1 DE68914698T DE68914698T DE68914698D1 DE 68914698 D1 DE68914698 D1 DE 68914698D1 DE 68914698 T DE68914698 T DE 68914698T DE 68914698 T DE68914698 T DE 68914698T DE 68914698 D1 DE68914698 D1 DE 68914698D1
Authority
DE
Germany
Prior art keywords
pharmacokinetics
proteins
charge
modification
changing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68914698T
Other languages
English (en)
Other versions
DE68914698T2 (de
Inventor
Alton C Morgan
Gowsala P Sivam
Paul G Abrams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of DE68914698D1 publication Critical patent/DE68914698D1/de
Application granted granted Critical
Publication of DE68914698T2 publication Critical patent/DE68914698T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE68914698T 1988-02-17 1989-02-17 Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung. Expired - Fee Related DE68914698T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/157,273 US5322678A (en) 1988-02-17 1988-02-17 Alteration of pharmacokinetics of proteins by charge modification

Publications (2)

Publication Number Publication Date
DE68914698D1 true DE68914698D1 (de) 1994-05-26
DE68914698T2 DE68914698T2 (de) 1994-08-25

Family

ID=22563038

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68914698T Expired - Fee Related DE68914698T2 (de) 1988-02-17 1989-02-17 Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung.

Country Status (5)

Country Link
US (1) US5322678A (de)
EP (1) EP0329185B1 (de)
JP (1) JPH0228200A (de)
AU (1) AU621342B2 (de)
DE (1) DE68914698T2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2518911B2 (ja) * 1987-10-23 1996-07-31 森永乳業株式会社 ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
US5635180A (en) * 1988-02-17 1997-06-03 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
CA2066031C (en) * 1989-09-29 2001-02-27 Mary A. Gray Methods for reducing non-target retention of immunoconjugates and metabolites thereof
US5130129A (en) * 1990-03-06 1992-07-14 The Regents Of The University Of California Method for enhancing antibody transport through capillary barriers
US5105528A (en) * 1991-01-22 1992-04-21 Universal Instruments Corporation Method and apparatus for supplying and changing tips of a pick and place vacuum spindle
US5869457A (en) * 1991-03-11 1999-02-09 Rijksuniversiteit Te Groningen Modified proteins and their use for controlling viral infections
AU2593192A (en) 1992-09-14 1994-04-12 Oystein Fodstad Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
NO180658C (no) 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
CA2190727C (en) * 1994-05-19 2006-07-18 Sudhakar Kasina Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
AU684348B2 (en) * 1994-06-07 1997-12-11 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
GR1002903B (el) * 1995-11-21 1998-05-12 Antisoma Limited Πεπτιδιο συγγενες με ογκο και ραδιενεργος διαγνωστικος παραγοντας και ραδιενεργος θεραπευτικος παραγοντας που περιεχει το πεπτιδιο.
NO961031D0 (no) * 1996-03-13 1996-03-13 Det Norske Radiumshospital Tum Fremgangsmåte til å drepe uönskede målceller
EP0938499A1 (de) * 1996-07-19 1999-09-01 Amgen Inc. Analoge von kationische proteine
US6271364B1 (en) 1999-02-23 2001-08-07 Amgen Inc. Analogs of NT-3
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
US6991788B1 (en) 1997-06-09 2006-01-31 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
AU752370B2 (en) * 1997-06-09 2002-09-19 Children's Hospital Of Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
AU2002231621A1 (en) * 2000-11-09 2002-05-21 Immunolex Laboratories Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
EP1426382A1 (de) * 2002-12-06 2004-06-09 Aventis Behring GmbH Antivirales menschliches Serum Albumin
WO2005016260A2 (en) * 2003-08-08 2005-02-24 The Regents Of The University Of California Prodrugs for the oral and parenteral delivery of amine-containing drugs, amino acids, and peptides
WO2006017427A1 (en) * 2004-08-03 2006-02-16 Becton, Dickinson And Company Use of magnetic material to fractionate samples
EP3050963B1 (de) * 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptiden durch regulierung der anordnung
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
CA2700986A1 (en) * 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
ES2834741T3 (es) * 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
US8937047B2 (en) * 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
US8124725B2 (en) 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
EP2409991B1 (de) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
BRPI1011145A2 (pt) 2009-05-15 2016-03-15 Chugai Pharmaceutical Co Ltd anticorpo anti-axl
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
RU2012134366A (ru) 2010-01-13 2014-02-20 ЭйПиТи ТЕРАПЬЮТИКС, ИНК. Терапевтические конструкции апиразы, средства на основе апиразы и способы получения
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
KR101398363B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
WO2012070964A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Модифицированные олигопептиды с противораковыми свойствами и способ их получения
EP2647706B1 (de) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP3050896B1 (de) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung eines polypeptid-heteromultimers
CN105018442A (zh) * 2014-04-23 2015-11-04 Apt治疗公司 改进的en-腺苷三磷酸双磷酸酶
AR100353A1 (es) 2014-05-08 2016-09-28 Chugai Pharmaceutical Co Ltd Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MY183415A (en) 2014-12-19 2021-02-18 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
BR112017014067B1 (pt) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
WO2017115773A1 (ja) 2015-12-28 2017-07-06 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720765A (en) * 1970-10-27 1973-03-13 Monsanto Co Crosslinked protein with acid anhydride as a ruminant feed material
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2340911A1 (de) * 1973-08-13 1975-05-07 Behringwerke Ag Tetanus-antigen und verfahren zu seiner herstellung
US4118379A (en) * 1974-09-06 1978-10-03 Behringwerke Aktiengesellschaft Amidated immune globulins and process for preparing them
US4082507A (en) * 1976-05-10 1978-04-04 Sawyer Philip Nicholas Prosthesis and method for making the same
US4168262A (en) * 1978-03-13 1979-09-18 Cornell Research Foundation, Inc. Anhydride modified microbial protein having reduced nucleic acid levels
US4218539A (en) * 1978-03-24 1980-08-19 Weltman Joel K Enzyme conjugates and method of preparation and use
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4501692A (en) * 1979-07-26 1985-02-26 Syva Company Charge effects in enzyme immunoassays
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4749570A (en) * 1981-12-31 1988-06-07 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
IT1150213B (it) * 1982-03-02 1986-12-10 Italfarmaco Spa Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
GR81790B (de) * 1983-04-29 1984-12-12 Omnichem Sa
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4560504A (en) * 1984-12-06 1985-12-24 Uop Inc. Carboxyl anchored immobilized antibodies
US5045303A (en) * 1985-05-17 1991-09-03 Neorx Corporation Radiohalogenated small molecules for protein labeling
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5151266A (en) * 1985-08-20 1992-09-29 Neorx Corporation Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies
CA1282069C (en) * 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
EP0268707A3 (de) * 1985-11-05 1989-03-08 The General Hospital Corporation Negativ geladene spezifische Affinitätsreagenzien
US5223242A (en) * 1985-11-05 1993-06-29 The General Hospital Corporation Negatively charged specific affinity reagents
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5084556A (en) * 1987-10-23 1992-01-28 Genetics Institute, Inc. Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5162505A (en) * 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration

Also Published As

Publication number Publication date
DE68914698T2 (de) 1994-08-25
EP0329185A3 (en) 1990-05-16
JPH0228200A (ja) 1990-01-30
AU621342B2 (en) 1992-03-12
EP0329185B1 (de) 1994-04-20
AU3006989A (en) 1989-08-17
EP0329185A2 (de) 1989-08-23
US5322678A (en) 1994-06-21

Similar Documents

Publication Publication Date Title
DE68914698D1 (de) Modifikation der Pharmakokinetika von Proteinen durch Ladungsänderung.
DE69008891D1 (de) Lagerung von Materialien.
NO902038D0 (no) Bitumenpolymerblandinger.
FI892714A (fi) Rekombinant-coccidiosisvaccin.
NO864139D0 (no) Polypeptid virksomt ved dannelse av aids-antistoff.
DE3879452D1 (de) Chimaere antikoerper.
DE68904679D1 (de) Elektroplattierung von kleinen partikeln.
DE3877862D1 (de) Bestimmung der ausrichtung von bauteilen.
NO892294L (no) Polypeptidforbindelser.
DE68916881D1 (de) Spursuchvorrichtung.
DE68924246D1 (de) Tonerzusammensetzung.
DE68912109D1 (de) Justierung von quadratursignalen.
ATE112172T1 (de) Targetformer von antitumor-methyltrithioagenzien.
DE68924932D1 (de) Piezoelektrische Vibrator-Komponente.
NO894193L (no) Partikkelformig vaskemiddelblanding.
NO890774D0 (no) Ekspresjon av hiv-bindende proteiner.
DE68921952D1 (de) Spannungsgesteuerter Oszillator.
DE68907500D1 (de) Spannungsgesteuerter oszillator.
NO892949L (no) Nye proteiner.
ATE125794T1 (de) Prodrogen von antiinflammatorischen 3-acyl-2- oxindol-1-carboxamiden.
DE69019244D1 (de) Ladungspumpe.
FI851488L (fi) Peptider.
NO892948D0 (no) Modifiserte proteiner.
NO883025D0 (no) Autodesinfiserende avformingsmaterialer.
DE3881991D1 (de) Zusammensetzung von gleitgliedern.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee